<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art>
   <ui>1742-4690-6-S3-P348</ui>
   <ji>1742-4690</ji>
   <fm>
      <dochead>Poster presentation</dochead>
      <bibl>
         <title>
            <p>P19-28. The V3 region of HIV-1: from NMR to vaccine design</p>
         </title>
         <aug>
            <au id="A1">
               <snm>Moseri</snm>
               <fnm>A</fnm>
               <insr iid="I2"/>
            </au>
            <au id="A2">
               <snm>Naider</snm>
               <fnm>F</fnm>
               <insr iid="I1"/>
            </au>
            <au ca="yes" id="A3">
               <snm>Anglister</snm>
               <fnm>J</fnm>
               <insr iid="I2"/>
            </au>
         </aug>
         <insg>
            <ins id="I1">
               <p>City University of New York, New York, USA</p>
            </ins>
            <ins id="I2">
               <p>Structural Biology, Weizmann Institute of Science, Rehovot, Israel</p>
            </ins>
         </insg>
         <source>Retrovirology</source>
         <supplement>
            <title>
               <p>AIDS Vaccine 2009</p>
            </title>
            <editor>Anna Laura Ross</editor>
            <note>Meeting abstracts &#8211; A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S3-full.pdf">here</a>.</note>
         </supplement>
         <conference>
            <title>
               <p>AIDS Vaccine 2009</p>
            </title>
            <location>Paris, France</location>
            <date-range>19&#8211;22 October 2009</date-range>
            <url>http://www.hivvaccineenterprise.org/conference/2009/index.aspx</url>
         </conference>
         <issn>1742-4690</issn>
         <pubdate>2009</pubdate>
         <volume>6</volume>
         <issue>Suppl 3</issue>
         <fpage>P348</fpage>
         <url>http://www.retrovirology.com/content/6/S3/P348</url>
         <xrefbib>
            <pubid idtype="doi">10.1186/1742-4690-6-S3-P348</pubid>
         </xrefbib>
      </bibl>
      <history>
         <pub>
            <date>
               <day>22</day>
               <month>10</month>
               <year>2009</year>
            </date>
         </pub>
      </history>
      <cpyrt>
         <year>2009</year>
         <collab>Moseri et al; licensee BioMed Central Ltd.</collab>
      </cpyrt>
   </fm>
   <bdy>
      <sec>
         <st>
            <p>Background</p>
         </st>
         <p>The V3 loop is one of the few epitopes to which broadly neutralizing antibody response can be directed. The most potent and most broadly neutralizing anti-V3 antibody to date is the human monoclonal antibody 447-52D. Using NMR spectroscopy, we studied the conformation of several V3 peptides in complex with 447-52D. The flexible V3 peptides were found to adopt a &#946;-hairpin conformation when bound to this antibody. Using disulfide bonds we constrained V3 peptides to adopt a conformation similar to those of V3 peptides bound to 447-52D.</p>
      </sec>
      <sec>
         <st>
            <p>Methods</p>
         </st>
         <p>Two cyclic peptides, P2 and P3, based on the consensus sequence of clade-B R5 viruses were synthesized in the form of a C4-V3 construct and compared with the linear peptide (P1). The peptide P2 was constrained by a disulfide bond at positions T303C/I323C and included the entire 447-52D epitope (R304-E322); the peptide P3 was constrained closer to the GPGR turn at positions K305C/T320C. Sera of rabbits immunized with these three peptides were tested for the ability to neutralize a panel of HIV-1 isolates.</p>
      </sec>
      <sec>
         <st>
            <p>Results</p>
         </st>
         <p>The peptide constrained at position T303C/I323C (P2) elicited a more potent HIV-1 neutralizing response in comparison with the linear P1 or the constrained peptide P3. All 4 sera of rabbits immunized with P2 neutralized 5 out of the 7 strains tested. For the SF162 strain, which differed by three mutations from the immunizing V3-peptide, 50% neutralization was achieved with average titers greater than 1,580, at least 20-fold and 40-fold better than the linear peptide (P1) and the other constrained peptide (P3) immune-sera, respectively.</p>
      </sec>
      <sec>
         <st>
            <p>Conclusion</p>
         </st>
         <p>We have demonstrated that constrained V3 peptides can elicit strong HIV-1 neutralizing response that is considerably more potent in comparison with linear peptide immune-sera given that the constraint is optimally located within the V3 epitope to include the entire V3 epitope recognized by the 447-52D antibody.</p>
      </sec>
   </bdy>
</art>

